Progress towards achieving new vaccine and vaccination goals
Identifieur interne : 001E18 ( Istex/Corpus ); précédent : 001E17; suivant : 001E19Progress towards achieving new vaccine and vaccination goals
Auteurs : G. AdaSource :
- Internal Medicine Journal [ 1444-0903 ] ; 2003-07.
Abstract
Abstract Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)
Url:
DOI: 10.1046/j.1445-5994.2003.00365.x
Links to Exploration step
ISTEX:1B63BBD000C189E1A70760C2BA528800C7D5D416Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Progress towards achieving new vaccine and vaccination goals</title><author><name sortKey="Ada, G" sort="Ada, G" uniqKey="Ada G" first="G." last="Ada">G. Ada</name><affiliation><mods:affiliation>John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1B63BBD000C189E1A70760C2BA528800C7D5D416</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1046/j.1445-5994.2003.00365.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001E18</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Progress towards achieving new vaccine and vaccination goals</title><author><name sortKey="Ada, G" sort="Ada, G" uniqKey="Ada G" first="G." last="Ada">G. Ada</name><affiliation><mods:affiliation>John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="ISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><imprint><biblScope unit="vol">33</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="297">297</biblScope><biblScope unit="page" to="304">304</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-07">2003-07</date></imprint><idno type="ISSN">1444-0903</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1444-0903</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>vaccine</json:string><json:string>immunisation</json:string><json:string>immune</json:string><json:string>lymphocyte</json:string><json:string>tumour</json:string><json:string>transgenic</json:string><json:string>infectious agent</json:string><json:string>autoimmune</json:string><json:string>engl</json:string><json:string>viral</json:string><json:string>prion</json:string><json:string>receptor</json:string><json:string>clinical trial</json:string><json:string>plasmid</json:string><json:string>immunotherapy</json:string><json:string>cytokine</json:string><json:string>internal medicine journal</json:string><json:string>immune response</json:string><json:string>vaccination</json:string><json:string>immune system</json:string><json:string>transgenic mouse</json:string><json:string>proc natl acad</json:string><json:string>allergic disease</json:string><json:string>adaptive system</json:string><json:string>vaccine development</json:string><json:string>conjugate vaccine</json:string><json:string>animal model</json:string><json:string>autoimmune disease</json:string><json:string>peptide</json:string><json:string>cell response</json:string><json:string>memory cell</json:string><json:string>chimeric plasmid</json:string><json:string>model system</json:string><json:string>cell epitope</json:string><json:string>world health organization</json:string><json:string>vaccination goal</json:string><json:string>spontaneous tumour</json:string><json:string>neurodegenerative disease</json:string><json:string>infection</json:string><json:string>viral titre</json:string><json:string>neutralizing antibody</json:string><json:string>capsular polysaccharide</json:string><json:string>effective vaccine</json:string><json:string>certain cytokine</json:string><json:string>respiratory syncytial virus</json:string><json:string>transcutaneous immunisation</json:string><json:string>lymph node</json:string><json:string>bacterial vaccine</json:string><json:string>transgenic potato</json:string><json:string>surface antigen</json:string><json:string>mouse immunised</json:string><json:string>parainfluenza virus</json:string><json:string>vaccine technology</json:string><json:string>other virus</json:string><json:string>candidate vaccine</json:string><json:string>streptococcus pneumoniae infection</json:string><json:string>chimeric virus</json:string><json:string>strong antibody</json:string><json:string>drug addiction</json:string><json:string>vaccine work</json:string><json:string>innate system</json:string><json:string>more difficult</json:string><json:string>many vaccine</json:string><json:string>human trial</json:string><json:string>current vaccine</json:string><json:string>other cell</json:string><json:string>australian national university</json:string><json:string>global eradication</json:string><json:string>early result</json:string><json:string>cervical cancer</json:string><json:string>genital wart</json:string><json:string>strong antibody response</json:string><json:string>specific antibody</json:string><json:string>ethnic african</json:string><json:string>early life</json:string><json:string>allergic reaction</json:string><json:string>first year</json:string><json:string>medical research</json:string><json:string>john curtin school</json:string><json:string>neuroblastoma cell</json:string><json:string>amino acid sequence</json:string><json:string>coding</json:string><json:string>allergic</json:string></teeft></keywords><author><json:item><name>G. Ada</name><affiliations><json:string>John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>infections</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>non‐infectious diseases</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>vaccination</value></json:item></subject><articleId><json:string>IMJ365</json:string></articleId><arkIstex>ark:/67375/WNG-184PWDX7-D</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Abstract Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)</abstract><qualityIndicators><score>8.596</score><pdfWordCount>6188</pdfWordCount><pdfCharCount>39187</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>8</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><pdfWordsPerPage>774</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>133</abstractWordCount><abstractCharCount>859</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Progress towards achieving new vaccine and vaccination goals</title><pmid><json:string>12823675</json:string></pmid><genre><json:string>review-article</json:string></genre><host><title>Internal Medicine Journal</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1445-5994</json:string></doi><issn><json:string>1444-0903</json:string></issn><eissn><json:string>1445-5994</json:string></eissn><publisherId><json:string>IMJ</json:string></publisherId><volume>33</volume><issue>7</issue><pages><first>297</first><last>304</last><total>8</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1930</json:string><json:string>during the nineteenth century</json:string><json:string>1990s</json:string><json:string>the twentieth century</json:string><json:string>1931</json:string><json:string>in the twentieth century</json:string><json:string>1977</json:string><json:string>2003</json:string><json:string>1980</json:string></date><geogName></geogName><orgName><json:string>World Health Organization.</json:string><json:string>Medical Research, Australian National University, Box</json:string><json:string>Canada and Finland</json:string><json:string>Anonymous.</json:string><json:string>World Health Organization</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Gordon Ada</json:string><json:string>Ada Table</json:string><json:string>Viral Smallpox</json:string><json:string>Burnet</json:string><json:string>Curtin School</json:string></persName><placeName><json:string>Ankara</json:string><json:string>Australia</json:string><json:string>Taiwan</json:string><json:string>Canberra</json:string><json:string>China</json:string><json:string>Europe</json:string><json:string>United Kingdom</json:string><json:string>York</json:string><json:string>Russia</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-184PWDX7-D</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, general & internal</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - general & internal medicine</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Internal Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1046/j.1445-5994.2003.00365.x</json:string></doi><id>1B63BBD000C189E1A70760C2BA528800C7D5D416</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Progress towards achieving new vaccine and vaccination goals</title><title level="a" type="short">Achieving new vaccination goals</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-07"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Progress towards achieving new vaccine and vaccination goals</title><title level="a" type="short">Achieving new vaccination goals</title><author xml:id="author-0000"><persName><forename type="first">G.</forename><surname>Ada</surname></persName><affiliation><orgName type="laboratory">John Curtin School of Medical Research</orgName><orgName type="institution">Australian National University</orgName><address><addrLine>Canberra</addrLine><addrLine>Australian Capital Territory, Australia</addrLine><country key="AU" xml:lang="en">AUSTRALIA</country></address></affiliation></author><idno type="istex">1B63BBD000C189E1A70760C2BA528800C7D5D416</idno><idno type="ark">ark:/67375/WNG-184PWDX7-D</idno><idno type="DOI">10.1046/j.1445-5994.2003.00365.x</idno><idno type="unit">IMJ365</idno><idno type="toTypesetVersion">file:IMJ.IMJ365.pdf</idno></analytic><monogr><title level="j" type="main">Internal Medicine Journal</title><title level="j" type="alt">INTERNAL MEDICINE JOURNAL</title><idno type="pISSN">1444-0903</idno><idno type="eISSN">1445-5994</idno><idno type="book-DOI">10.1111/(ISSN)1445-5994</idno><idno type="book-part-DOI">10.1111/imj.2003.33.issue-7</idno><idno type="product">IMJ</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">33</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="297">297</biblScope><biblScope unit="page" to="304">304</biblScope><biblScope unit="page-count">8</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2003-07"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p>
<hi rend="bold">Abstract</hi>
</p><p>Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">infections</term><term xml:id="k2">non‐infectious diseases</term><term xml:id="k3">vaccines</term><term xml:id="k4">vaccination</term></keywords><keywords rend="tocHeading1"><term>Reviews</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Pty</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1445-5994</doi><issn type="print">1444-0903</issn><issn type="electronic">1445-5994</issn><idGroup><id type="product" value="IMJ"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="INTERNAL MEDICINE JOURNAL">Internal Medicine Journal</title></titleGroup></publicationMeta><publicationMeta level="part" position="07007"><doi origin="wiley">10.1111/imj.2003.33.issue-7</doi><numberingGroup><numbering type="journalVolume" number="33">33</numbering><numbering type="journalIssue" number="7">7</numbering></numberingGroup><coverDate startDate="2003-07">July 2003</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="0029700" status="forIssue"><doi origin="wiley">10.1046/j.1445-5994.2003.00365.x</doi><idGroup><id type="unit" value="IMJ365"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="tocHeading1">Reviews</title></titleGroup><eventGroup><event type="firstOnline" date="2003-07-01"></event><event type="publishedOnlineFinalForm" date="2003-07-01"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-02-27"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-28"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="297">297</numbering><numbering type="pageLast" number="304">304</numbering></numberingGroup><correspondenceTo><i>Gordon Ada, John Curtin School of Medical Research, Australian National University, Box 334, Canberra, ACT, 2601, Australia.</i> Email: <email>gordon.ada@anu.edu.au</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IMJ.IMJ365.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory><i>Received 10 May 2002;</i> <i>accepted 11 September 2002.</i></unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="3"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="56"></count><count type="wordTotal" number="5472"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Progress towards achieving new vaccine and vaccination goals</title><title type="shortAuthors">Ada</title><title type="short">Achieving new vaccination goals</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>G.</givenNames><familyName>Ada</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="AU"><unparsedAffiliation>John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">infections</keyword><keyword xml:id="k2">non‐infectious diseases</keyword><keyword xml:id="k3">vaccines</keyword><keyword xml:id="k4">vaccination</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p> <b>Abstract</b> </p><p>Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1" numbered="no"><p>Funding: None</p><p>Conflicts of interest: None</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Progress towards achieving new vaccine and vaccination goals</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Achieving new vaccination goals</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Progress towards achieving new vaccine and vaccination goals</title></titleInfo><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Ada</namePart><affiliation>John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Science Pty</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2003-07</dateIssued><edition>Received 10 May 2002; accepted 11 September 2002.</edition><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">3</extent><extent unit="formulas">0</extent><extent unit="references">56</extent><extent unit="linksCrossRef">0</extent><extent unit="words">5472</extent></physicalDescription><abstract lang="en">Abstract Viral and bacterial vaccines, especially for childhood use, are one of the most successful public health measures of the last two centuries and have a good safety record. However, there are still many diseases that are caused by infectious agents for which vaccines are not available. Our increasing ability to manipulate the immune system offers hope that, in the future, at least some of these infections may be prevented by vaccination. A surprising recent development is the use of vaccine technology to test whether a range of other generally non‐communicable diseases can be prevented (or at least controlled) in this way. Investigation of these diseases is still mainly at the experimental level, however the list includes different types of cancers, allergies, drug addiction and neurodegenerative diseases. (Intern Med J 2003; 33: 297−304)</abstract><subject lang="en"><genre>keywords</genre><topic>infections</topic><topic>non‐infectious diseases</topic><topic>vaccines</topic><topic>vaccination</topic></subject><relatedItem type="host"><titleInfo><title>Internal Medicine Journal</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1444-0903</identifier><identifier type="eISSN">1445-5994</identifier><identifier type="DOI">10.1111/(ISSN)1445-5994</identifier><identifier type="PublisherID">IMJ</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>297</start><end>304</end><total>8</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Vaccines in historic evolution and perspective: a narrative of vaccine discoveries</title></titleInfo><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Hilleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000; 18: 1436−47.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1436</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1436</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Ada G, Ramsay A. Vaccines, Vaccination and the Immune Response.Philadelphia:Lippincott‐Raven;1997.</title></titleInfo><note type="citation/reference">Ada G, Ramsay A. Vaccines, Vaccination and the Immune Response. Philadelphia: Lippincott‐Raven; 1997.</note><name type="personal"><namePart type="given">G</namePart><namePart type="family">Ada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ramsay</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>Philadelphia:</publisher></originInfo><part><date>1997</date></part></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Anonymous.The Jordan Report. Accelerated Development of Vaccines. Division of Microbiology and Infectious Diseases. Washington:National Institutes of Health;2000.</title></titleInfo><name type="corporate"><namePart>Anonymous.</namePart></name><note type="citation/reference">Anonymous. The Jordan Report. Accelerated Development of Vaccines. Division of Microbiology and Infectious Diseases. Washington: National Institutes of Health; 2000.</note><genre>book</genre><originInfo><publisher>Washington:</publisher></originInfo><part><date>2000</date></part></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Vaccines vaccination</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Ada</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ada G. Vaccines vaccination. N Engl J Med 2001; 345: 1042−53.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>1042</start><end>53</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>1042</start><end>53</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Summary of notifiable diseases, United States</title></titleInfo><name type="corporate"><namePart>Anonymous.</namePart></name><genre>journal-article</genre><note type="citation/reference">Anonymous. Summary of notifiable diseases, United States. Morb Mortal Wkly Rep 1998; 47 (suppl.): 1−92.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>suppl.</number></detail><extent unit="pages"><start>1</start><end>92</end></extent></part><relatedItem type="host"><titleInfo><title>Morb Mortal Wkly Rep</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><detail type="issue"><caption>no.</caption><number>suppl.</number></detail><extent unit="pages"><start>1</start><end>92</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Chemo‐immunological studies on conjugated carbohydrate proteins, V: the immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein</title></titleInfo><name type="personal"><namePart type="given">OT</namePart><namePart type="family">Avery</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WF</namePart><namePart type="family">Goebel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Avery OT, Goebel WF. Chemo‐immunological studies on conjugated carbohydrate proteins, V: the immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J Exp Med 1931; 64: 437−47.</note><part><date>1931</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>437</start><end>47</end></extent></part><relatedItem type="host"><titleInfo><title>J Exp Med</title></titleInfo><part><date>1931</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>437</start><end>47</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Haemophilus influenzae vaccines</title></titleInfo><name type="personal"><namePart type="given">JI</namePart><namePart type="family">Ward</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KM</namePart><namePart type="family">Zangwill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Vaccines</title></titleInfo><originInfo><publisher>Philadelphia:</publisher></originInfo><part><date>1999</date><extent unit="pages"><start>183</start><end>221</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Pneumococcal conjugate vaccine Prevnar TMI; PNCRM7. A review of its use in the prevention of Streptococcus pneumoniae infection</title></titleInfo><name type="personal"><namePart type="given">MJM</namePart><namePart type="family">Darkes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GL</namePart><namePart type="family">Plosker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Darkes MJM, Plosker GL. Pneumococcal conjugate vaccine Prevnar TMI; PNCRM7. A review of its use in the prevention of Streptococcus pneumoniae infection. Pediatr Drugs 2002; 4: 609−30.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>609</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Drugs</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>609</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England</title></titleInfo><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Ramsay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Andrews</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EB</namePart><namePart type="family">Keezmarsk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ramsay ME, Andrews N, Keezmarsk EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195−6.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>195</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>357</number></detail><extent unit="pages"><start>195</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>The efficacy of a Salmonella Vi conjugate vaccine in two‐to‐five‐year‐old children</title></titleInfo><name type="personal"><namePart type="given">FYC</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Ho</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HB</namePart><namePart type="family">Kheim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Ha</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DT</namePart><namePart type="family">Dang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PV</namePart><namePart type="family">Bay</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lin FYC, Ho V, Kheim HB, Ha B, Dang DT, Bay PV et al. The efficacy of a Salmonella Vi conjugate vaccine in two‐to‐five‐year‐old children. N Engl J Med 2001; 344: 1263−9.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>1263</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>1263</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>World Health Organization.World Health Report.Geneva:World Health Organization;1998.</title></titleInfo><name type="corporate"><namePart>World Health Organization.</namePart></name><note type="citation/reference">World Health Organization. World Health Report. Geneva: World Health Organization; 1998.</note><genre>book</genre><originInfo><publisher>Geneva:</publisher></originInfo><part><date>1998</date></part></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Respiratory syncytial virus and parainfluenza virus</title></titleInfo><name type="personal"><namePart type="given">CB</namePart><namePart type="family">Hall</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344; 1917−28.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>1917</start><end>28</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>1917</start><end>28</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Innate immunity</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Medzhitov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Janeway</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000; 343: 338−44.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>343</number></detail><extent unit="pages"><start>338</start><end>44</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>343</number></detail><extent unit="pages"><start>338</start><end>44</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>The immune system. First of two parts</title></titleInfo><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Delves</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IM</namePart><namePart type="family">Roitt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343: 37−49.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>343</number></detail><extent unit="pages"><start>37</start><end>49</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>343</number></detail><extent unit="pages"><start>37</start><end>49</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Crystal structure of a neutralizing human IgG against HIV‐1: a template for vaccine design</title></titleInfo><name type="personal"><namePart type="given">EO</namePart><namePart type="family">Saphire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PWHI</namePart><namePart type="family">Parren</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Pantophlet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MB</namePart><namePart type="family">Zwick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GM</namePart><namePart type="family">Morris</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Ruod</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Ruod PM et al. Crystal structure of a neutralizing human IgG against HIV‐1: a template for vaccine design. Science 2001; 293: 1155−8.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>1155</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>293</number></detail><extent unit="pages"><start>1155</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Containing HIV after infection</title></titleInfo><name type="personal"><namePart type="given">BD</namePart><namePart type="family">Walker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ES</namePart><namePart type="family">Rosenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walker BD, Rosenberg ES. Containing HIV after infection. Nature Med 2000; 6: 1094−5.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1094</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Nature Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1094</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Transcutaneous immunisation; a human vaccine delivery strategy using a patch</title></titleInfo><name type="personal"><namePart type="given">GM</namePart><namePart type="family">Glenn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DN</namePart><namePart type="family">Taylor</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Li</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Frankel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Montemarano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Alving</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR et al. Transcutaneous immunisation; a human vaccine delivery strategy using a patch. Nature Med 2000; 6: 1403−7.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1403</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Nature Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>1403</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Plant biotechnology: new procedures and applications</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hammond</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">McGarvey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Yusibov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hammond J, McGarvey P, Yusibov V. Plant biotechnology: new procedures and applications. Contemp Top Mol Immunol 1999; 240: 1−196.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>240</number></detail><extent unit="pages"><start>:</start></extent></part><relatedItem type="host"><titleInfo><title>Contemp Top Mol Immunol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>240</number></detail><extent unit="pages"><start>:</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Oral immunisation with hepatitis B surface antigen expressed in transgenic plants</title></titleInfo><name type="personal"><namePart type="given">Q</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Richter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YF</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CJ</namePart><namePart type="family">Arntzen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Mason</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Thanavala</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y et al. Oral immunisation with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci 2001; 98: 11539−44.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>11539</start><end>44</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>11539</start><end>44</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>New multi‐determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population</title></titleInfo><name type="personal"><namePart type="given">ER</namePart><namePart type="family">Brandt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KS</namePart><namePart type="family">Sriprakash</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RI</namePart><namePart type="family">Hobb</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Hayman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Zeng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Batzloff</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR et al. New multi‐determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nature Med 2000; 6: 455−9.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>455</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Nature Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>455</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>A wholly synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types</title></titleInfo><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Nardin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Calco‐Calle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Oliveira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RS</namePart><namePart type="family">Nussenzweig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schweider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Tiercy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nardin EH, Calco‐Calle JM, Oliveira GA, Nussenzweig RS, Schweider M, Tiercy JM et al. A wholly synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J Immunol 2001; 166: 481−9.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>481</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>166</number></detail><extent unit="pages"><start>481</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Expression of mouse interleukin‐4 by a recombinant ectromelia virus suresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Jackson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Ramsay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CD</namePart><namePart type="family">Christensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Beaton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DF</namePart><namePart type="family">Hall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IR</namePart><namePart type="family">Ramshaw</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IR et al. Expression of mouse interleukin‐4 by a recombinant ectromelia virus suresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75: 1205−10.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>1205</start><end>10</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>1205</start><end>10</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Molecular medicine: DNA Vaccines</title></titleInfo><name type="personal"><namePart type="given">WM</namePart><namePart type="family">McDonnell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FK</namePart><namePart type="family">Askari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McDonnell WM, Askari FK. Molecular medicine: DNA Vaccines. N Engl J Med 1995; 334: 42−5.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>334</number></detail><extent unit="pages"><start>42</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>334</number></detail><extent unit="pages"><start>42</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Induction of CD4+ T cell‐dependent CD8+ type 1 responses in humans by a malaria DNA vaccine</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Epstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FM</namePart><namePart type="family">Baraceros</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Gorack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Charoenvit</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Carucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang R, Epstein J, Baraceros FM, Gorack EJ, Charoenvit Y, Carucci DJ et al. Induction of CD4+ T cell‐dependent CD8+ type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci 2001; 98: 10817−1822.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>10817</start><end>1822</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>10817</start><end>1822</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">O'Hagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Singh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ugozzoli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Wild</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Barnett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001; 75: 9037−43.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>9037</start><end>43</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>9037</start><end>43</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox virus</title></titleInfo><name type="personal"><namePart type="given">KH</namePart><namePart type="family">Leong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Ramsay</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Morin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IR</namePart><namePart type="family">Ramshaw</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Vaccines, ’95.</title></titleInfo><originInfo><publisher>Cold Spring Harbour:</publisher></originInfo><part><date>1995</date><extent unit="pages"><start>327</start><end>31</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection</title></titleInfo><name type="personal"><namePart type="given">TM</namePart><namePart type="family">Wizemann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Heinrichs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Adamou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Erwin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Kunscu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GH</namePart><namePart type="family">Chol</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wizemann TM, Heinrichs JH, Adamou J, Erwin AL, Kunscu C, Chol GH et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Inf Immun 2001; 69: 1593−8.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>1593</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Inf Immun</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>1593</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Talwar GP, Raghupathy R, eds. Birth Control Vaccines.Austin:R. G. Landes Co.;1995.</title></titleInfo><note type="citation/reference">Talwar GP, Raghupathy R, eds. Birth Control Vaccines. Austin: R. G. Landes Co.; 1995.</note><name type="personal"><namePart type="given">GP</namePart><namePart type="family">Talwar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Raghupathy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>Austin:</publisher></originInfo><part><date>1995</date></part></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group</title></titleInfo><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CJ</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Lai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H‐M</namePart><namePart type="family">Hsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TC</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M‐S</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang MH, Chen CJ, Lai MS, Hsu H‐M, Wu TC, Kong M‐S et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855−959.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>336</number></detail><extent unit="pages"><start>1855</start><end>959</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>336</number></detail><extent unit="pages"><start>1855</start><end>959</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>A controlled trial of a human papilloma virus type 16 vaccine</title></titleInfo><name type="personal"><namePart type="given">LA</namePart><namePart type="family">Koutsky</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KA</namePart><namePart type="family">Ault</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Wheeler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Brown</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Barr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FB</namePart><namePart type="family">Alvarez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koutsky, LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papilloma virus type 16 vaccine. N Engl J Med 2002; 347: 1645−51.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1645</start><end>51</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1645</start><end>51</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>HPV vaccine highly effective</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Quirk</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Quirk M. HPV vaccine highly effective. Lancet Infect Dis 2003; 3: 181.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>181</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet Infect Dis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>181</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>HPV 6b virus‐like particles are potent immunogens without adjuvant in man</title></titleInfo><name type="personal"><namePart type="given">LF</namePart><namePart type="family">Zhang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Chen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LL</namePart><namePart type="family">Cai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">QY</namePart><namePart type="family">Bao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Zheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhang LF, Zhou J, Chen S, Cai LL, Bao QY, Zheng Y et al. HPV 6b virus‐like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18: 1051−8.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1051</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>1051</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Epidemiologic classification of human papillomavirus types associated with cervical cancer</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Munoz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FX</namePart><namePart type="family">Bosch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">DeSanjose</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Herrero</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">X</namePart><namePart type="family">Castellsague</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KV</namePart><namePart type="family">Shah</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Munoz N, Bosch FX, DeSanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518−27.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>518</start><end>27</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>518</start><end>27</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>The immunology of Epstein‐Barr virus infection</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Moss</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Burrows</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Silins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Misko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Khanna</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. The immunology of Epstein‐Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001; 356: 475−88.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>475</start><end>88</end></extent></part><relatedItem type="host"><titleInfo><title>Philos Trans R Soc Lond B Biol Sci</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>356</number></detail><extent unit="pages"><start>475</start><end>88</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>The concept of immunological tolerance</title></titleInfo><name type="personal"><namePart type="given">FM</namePart><namePart type="family">Burnet</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnet FM. The concept of immunological tolerance. Prog Exp Tumor Res 1970; 13: 1−27.</note><part><date>1970</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1</start><end>27</end></extent></part><relatedItem type="host"><titleInfo><title>Prog Exp Tumor Res</title></titleInfo><part><date>1970</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>1</start><end>27</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Shankaran</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ikeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AT</namePart><namePart type="family">Bruce</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">White Jm Swanson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Old</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Schrelber</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shankaran V, Ikeda H, Bruce AT, White Jm Swanson PE, Old LJ, Schrelber D et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107−11.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>410</number></detail><extent unit="pages"><start>1107</start><end>11</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>410</number></detail><extent unit="pages"><start>1107</start><end>11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Vaccination of melanoma patients with peptide or tumor lysate‐pulsed dendritic cells</title></titleInfo><name type="personal"><namePart type="given">FO</namePart><namePart type="family">Nestle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Alijagic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Gilliet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Grabbe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Dummer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R et al. Vaccination of melanoma patients with peptide or tumor lysate‐pulsed dendritic cells. Nature Med 1998; 4: 328−32.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>328</start><end>32</end></extent></part><relatedItem type="host"><titleInfo><title>Nature Med</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>328</start><end>32</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Dendritic cell vaccines for cancer immunotherapy</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Timmerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Levy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med 1999; 60: 507−30.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>507</start><end>30</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rev Med</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>507</start><end>30</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Tumor‐specific immunity and anti‐angiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen</title></titleInfo><name type="personal"><namePart type="given">W‐F</namePart><namePart type="family">Cheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C‐F</namePart><namePart type="family">Hung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C‐Y</namePart><namePart type="family">Chai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K‐F</namePart><namePart type="family">Hsu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ling</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cheng W‐F, Hung C‐F, Chai C‐Y, Hsu K‐F, He L, Ling M et al. Tumor‐specific immunity and anti‐angiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001; 108: 669−78.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>669</start><end>78</end></extent></part><relatedItem type="host"><titleInfo><title>J Clin Invest</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>108</number></detail><extent unit="pages"><start>669</start><end>78</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Advances in immunology: Autoimmune diseases</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Davidson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Diamond</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Davidson A, Diamond B. Advances in immunology: Autoimmune diseases. N Engl J Med 2001; 345: 340−9.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>340</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>345</number></detail><extent unit="pages"><start>340</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Successful TCR‐based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Matsumoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Jee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Sugisaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Matsumoto Y, Jee Y, Sugisaki M. Successful TCR‐based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J Immunol 2000; 164: 2248−54.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>2248</start><end>54</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>164</number></detail><extent unit="pages"><start>2248</start><end>54</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Give us this day our daily germs</title></titleInfo><name type="personal"><namePart type="given">GAW</namePart><namePart type="family">Rook</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Stanford</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rook GAW, Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 113−6.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>113</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Immunol Today</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>113</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>The effect of vaccination with DNA encoding murine T‐cell epitopes on the DER p1 and 2 induced IgE synthesis</title></titleInfo><name type="personal"><namePart type="given">SS</namePart><namePart type="family">Kwon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Yoo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kwon SS, Kim N, Yoo TJ. The effect of vaccination with DNA encoding murine T‐cell epitopes on the DER p1 and 2 induced IgE synthesis. Allergy 2001; 56: 741−8.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>741</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>741</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Measles and atopy in Guinea‐Bissau</title></titleInfo><name type="personal"><namePart type="given">SO</namePart><namePart type="family">Shaheen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Aaby</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ</namePart><namePart type="family">Hall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJP</namePart><namePart type="family">Barker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CB</namePart><namePart type="family">Heyes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AW</namePart><namePart type="family">Sheill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shaheen SO, Aaby P, Hall AJ, Barker DJP, Heyes CB, Sheill AW et al. Measles and atopy in Guinea‐Bissau. Lancet 1996; 347: 1792−6.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1792</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1792</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Heterogeneity in DTaP vaccine‐specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Thi function</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Rowe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Macaubas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Monger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ</namePart><namePart type="family">Holt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Harvey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JT</namePart><namePart type="family">Poolman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rowe J, Macaubas C, Monger T, Holt PJ, Harvey J, Poolman JT et al. Heterogeneity in DTaP vaccine‐specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Thi function. J Infect Dis 2001; 184: 80−88.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>184</number></detail><extent unit="pages"><start>80</start><end>88</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>184</number></detail><extent unit="pages"><start>80</start><end>88</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Exposure to farming in early life and development of asthma and allergy: a cross‐sectional survey</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Riedler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Braun‐Fahrlander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Eder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Schreuer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Waser</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Maisch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Riedler J, Braun‐Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S et al. Exposure to farming in early life and development of asthma and allergy: a cross‐sectional survey. Lancet, 2001; 358: 1129−33.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>1129</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>358</number></detail><extent unit="pages"><start>1129</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>A second‐generation vaccine protects against the psychoactive effects of cocaine</title></titleInfo><name type="personal"><namePart type="given">MRA</namePart><namePart type="family">Carrera</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Ashley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Wirsching</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GF</namePart><namePart type="family">Kooh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KG</namePart><namePart type="family">Janda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carrera MRA, Ashley JA, Wirsching P, Kooh GF, Janda KG. A second‐generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 2001; 98: 1988−92.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>1988</start><end>92</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci USA</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>1988</start><end>92</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Titer‐dependent antagonism of cocaine following active immunisation in rhesus monkeys</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Koetzner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Deng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TL</namePart><namePart type="family">Sumpter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Weisslitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RT</namePart><namePart type="family">Hener</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DW</namePart><namePart type="family">Landry</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koetzner L, Deng S, Sumpter TL, Weisslitz M, Hener RT, Landry DW et al. Titer‐dependent antagonism of cocaine following active immunisation in rhesus monkeys. J Pharmacol Exp Therapeut 2001; 296: 789−96.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>296</number></detail><extent unit="pages"><start>789</start><end>96</end></extent></part><relatedItem type="host"><titleInfo><title>J Pharmacol Exp Therapeut</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>296</number></detail><extent unit="pages"><start>789</start><end>96</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Nicotine vaccine enters human trials</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Randerson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Randerson J. Nicotine vaccine enters human trials. New Scientist 2001; 171: 7.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>7</start></extent></part><relatedItem type="host"><titleInfo><title>New Scientist</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>171</number></detail><extent unit="pages"><start>7</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Morgon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DM</namePart><namePart type="family">Diamond</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PE</namePart><namePart type="family">Gottschall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Ugen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Dickey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Hardy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morgon D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982−5.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>408</number></detail><extent unit="pages"><start>982</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>408</number></detail><extent unit="pages"><start>982</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Immunisation with amyloid β attenuates Alzheimer disease‐like pathology in the PDA mouse</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Schenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Barbour</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">Dunn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Gordon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Grajeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Guido</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al. Immunisation with amyloid β attenuates Alzheimer disease‐like pathology in the PDA mouse. Nature 1999; 400: 173−7.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>400</number></detail><extent unit="pages"><start>173</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>400</number></detail><extent unit="pages"><start>173</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Imaging of amyloid β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy</title></titleInfo><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Bacskai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Kajdasz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RH</namePart><namePart type="family">Christie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Carter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Games</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Seubert</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert B et al. Imaging of amyloid β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nature Med 2001; 7: 369−72.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>369</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Nature Med</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>369</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>β‐Amyloid peptides enhance a‐synuclein accumulation and neuronal defects in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Masliah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Rockenstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Veinbergs</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Sagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Mallory</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Masliah E, Rockenstein E, Veinbergs I, Sagan Y, Mallory M. β‐Amyloid peptides enhance a‐synuclein accumulation and neuronal defects in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci 2001; 98: 12245−50.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>12245</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>12245</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Antibodies inhibit prion propagation and clear cell cultures of prion infectivity</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Peretz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Williamson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Kaneko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Vergara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Leclerc</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Schmitt‐Ulms</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt‐Ulms G et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739−42.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>412</number></detail><extent unit="pages"><start>739</start><end>42</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>412</number></detail><extent unit="pages"><start>739</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Scrapie prion protein accumulation by scrapie‐infected neuroblastoma cells abrogated by exposure to a prion protein antibody</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Enari</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Flechsig</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Weissmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie‐infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci 2001; 16: 9295−9.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>9295</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>9295</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Prevention of scrapie pathogenesis by transgenic expression of anti‐prion antibodies</title></titleInfo><name type="personal"><namePart type="given">FL</namePart><namePart type="family">Hener</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Musahl</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Arrighi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Klein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Rulicke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Oesch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hener FL, Musahl C, Arrighi I, Klein MA, Rulicke T, Oesch B et al. Prevention of scrapie pathogenesis by transgenic expression of anti‐prion antibodies. Science 2001; 294: 178−82.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>178</start><end>82</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>178</start><end>82</end></extent></part></relatedItem></relatedItem><identifier type="istex">1B63BBD000C189E1A70760C2BA528800C7D5D416</identifier><identifier type="ark">ark:/67375/WNG-184PWDX7-D</identifier><identifier type="DOI">10.1046/j.1445-5994.2003.00365.x</identifier><identifier type="ArticleID">IMJ365</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-184PWDX7-D/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001E18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1B63BBD000C189E1A70760C2BA528800C7D5D416
|texte= Progress towards achieving new vaccine and vaccination goals
}}
| This area was generated with Dilib version V0.6.34. |  |